Skip to main content
. 2014 Oct;58(10):6024–6031. doi: 10.1128/AAC.02310-13

FIG 3.

FIG 3

Emergence of resistance during drug administration versus clinical isolate PAE 2638. Panel A shows the negative-control (no treatment) and active-control (piperacillin-tazobactam at 4.5 g Q6h) study arms, while panel B shows ceftolozane-tazobactam (TOL/TAZ) regimens ranging from 62.5/31.25 to 2,000/1,000 mg delivered Q8h.